STI 1386
Alternative Names: STI-1386Latest Information Update: 27 Jan 2023
At a glance
- Originator Sorrento Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I CNS cancer; Solid tumours
Most Recent Events
- 27 Jan 2023 Phase-I clinical trials in CNS cancer in USA (Parenteral) (Sorrento Therapeutics pipeline, January 2023)
- 27 Jan 2023 Phase-I clinical trials in Solid tumours in USA (Parenteral) (Sorrento Therapeutics pipeline, January 2023)
- 05 Apr 2022 Sorrento Therapeutics plans to initiates enrolment in a phase-Ib trial for relapsed or refractory solid tumours in the first quarter of 2022